|
UMass Medical School psychopharmacology expert Anthony Rothschild, MD, will become an editor-in-chief of the Journal of Clinical Psychopharmacology on Jan. 1, journal publisher Wolters Kluwer has announced.
“It is a tremendous honor and responsibility to join the editorial leadership of the journal,” said Dr. Rothschild, the Irving S. and Betty Brudnick Endowed Chair in Psychiatry, professor of psychiatry and vice chair for research for the department. “During my 24 years at the Medical School I have been given a tremendous opportunity to grow as a clinician, researcher, teacher and mentor. I wish to thank my many wonderful colleagues, including my students and residents, and the Brudnick family, whose support has culminated in this appointment.”
The Brudnick family endowed the professorship and a research institute in appreciation of Rothschild, who successfully treated Mr. Brudnick for major depression. Rothschild’s clinical research has advanced scientific knowledge on the pathophysiology of treatment-resistant depressive disorders and major depression with psychotic features.
“I will seek to build on the foundation laid and to publish cutting-edge research in psychopharmacology that will impact our field,” said Rothschild. “I believe the strength of the Journal of Clinical Psychopharmacology is the combination of its clinical focus, which directly impacts patient care, along with scientific advances with clinical applications.”
Rothschild is an elected fellow of the American College of Neuropsychopharmacology and the International College of Neuropsychopharmacology, which are the national and international scientific organizations for the study and treatment of psychiatric illnesses with psychotropic medications. He has authored dozens of scholarly papers and edited five books, including The Evidence-Based Guide to Antidepressant Medications and The Evidence-Based Guide to Antipsychotic Medications, two widely used references for clinicians across disciplines that include guidelines for prescribing to special populations such as children and adolescents, geriatric patients, and pregnant and lactating women.
“Dr. Rothschild has established an international reputation for his expertise in major depression with psychotic features and has mentored a generation of faculty and trainees in psychopharmacology research at Harvard, at UMass and beyond,” said Sheldon Benjamin, MD, interim chair and professor of psychiatry. “The Department of Psychiatry is proud to see Tony’s impact on the field of psychopharmacology recognized by his selection as editor-in-chief of this prestigious journal.”
Related story on UMassMed News:
New developments in depression research with Anthony Rothschild
Continuation of combination drug therapy for psychotic depression reduces relapse risk, JAMA study shows
